as CFO, Mr. Siegel will be responsible for the financial management and
reporting of Biotest Pharmaceuticals. To facilitate the transition
period for Nabi Biopharmaceuticals, Mr. Siegel also will continue to
hold the position of CFO at Nabi through March 2008.
-- Vice President of Project Management - Peter Seith. Mr. Seith
previously served as one of the Directors of Project Management for
Biotest Pharma GmbH. Prior to that, he was the Director of Quality
Assurance at CSL Behring. Mr. Seith will serve a dual role responsible
for both project management for Biotest Pharmaceuticals in Boca Raton
and Vice President of Corporate Quality Assurance for Biotest Pharma
"Biotest Pharmaceuticals draws upon the success and experience of two established leaders in the field of immunology and plasma products -- our parent company, Biotest AG, and Nabi Biopharmaceuticals," said Dr. Rainer Pabst, Chief Executive Officer of Biotest Pharmaceuticals. "With the completion of our acquisition of Nabi's Biologics business, pipeline and key assets, we feel we are founding Biotest Pharmaceuticals with a solid foundation, a high quality workforce, state-of-the-art facilities and a promising pipeline of biotherapeutic products. We look forward to realizing our potential and driving the growth of Biotest Pharmaceuticals as we move forward together."
About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation develops and manufactures
pharmaceutical and biotherapeutic products with a specialization in
immunology. Biotest Pharmaceuticals will offer the hyperimmunoglobulin
Nabi- HB(R), a key product used in the prevention of hepatitis B. Biotest
Pharmaceuticals also is currently working to develop additional products
including a polyvalent immunoglobulin (IVIG, Phase III) and Civacir(R)
(Phase IIb), for the p
|SOURCE Biotest Pharmaceuticals Corp.|
Copyright©2007 PR Newswire.
All rights reserved